RxDoctor Payments Data

Martin White, MD

Internal Medicine · Houston, TXNPI 1518944545

Payments from drug & device makers

$1,225in general payments, 2019–2025

Across 61 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$316
  • AbbVie$127
  • GSK$97
  • Amneal Pharmaceuticals LLC$96
  • Lilly USA, LLC$69
  • Optinose US, Inc.$66
  • plus $455 from 17 others

What the payments were for

  • Food & beverage$1,225100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,225 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$233,657
Medicare patients
698
Services billed
15,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban207$161,791
OzempicSemaglutide96$89,277
JardianceEmpagliflozin75$66,914
XareltoRivaroxaban47$43,822
JanuviaSitagliptin Phosphate41$26,587
TrulicityDulaglutide12$16,423
FarxigaDapagliflozin Propanediol11$15,951
SynthroidLevothyroxine Sodium182$13,962
MultaqDronedarone Hcl14$11,522
MyrbetriqMirabegron14$9,261
Levothyroxine Sodium607$7,844
PremarinEstrogens, Conjugated22$7,256
Rosuvastatin Calcium417$5,487
Pravastatin Sodium348$4,905
Lisinopril611$4,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$13$170,477308 claims
Novo NordiskOzempic$316$89,27796 claims
Johnson & JohnsonXarelto$29$43,82247 claims
MerckJanuvia$17$26,58741 claims
Lilly USA, LLCTrulicity$69$16,42312 claims
AstraZenecaFarxiga$30$15,95111 claims
AbbVieSynthroid$127$13,962182 claims
Sanofi-aventis U.S. LLCMultaq$17$11,52214 claims
Astellas Pharma US IncMyrbetriq$18$9,26114 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$96$7,844607 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →